Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review

Cornford, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer, Eur Urol, 71, 630, 10.1016/j.eururo.2016.08.002

Halabi, 2016, Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer, J Clin Oncol, 34, 1652, 10.1200/JCO.2015.65.7270

Ost, 2014, Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer, Prostate, 74, 297, 10.1002/pros.22750

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Steuber T, Jilg C, Tennstedt P, et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.02.015.

Ploussard, 2015, Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature, J Urol, 194, 983, 10.1016/j.juro.2015.04.103

Rinnab, 2008, [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study, Urol Int, 81, 191, 10.1159/000144059

Schilling, 2008, Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer, BJU Int, 102, 446, 10.1111/j.1464-410X.2008.07592.x

Winter, 2010, First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy, Urol Int, 84, 418, 10.1159/000296298

Rigatti, 2011, Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography, Eur Urol, 60, 935, 10.1016/j.eururo.2011.07.060

Jilg, 2012, Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer, J Urol, 188, 2190, 10.1016/j.juro.2012.08.041

Karnes, 2015, Salvage lymph node dissection for prostate cancer nodal recurrence detected by (11)c-choline positron emission tomography/computerized tomography, J Urol, 193, 111, 10.1016/j.juro.2014.08.082

Jilg, 2014, Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer, Radiat Oncol, 9, 178, 10.1186/1748-717X-9-178

Suardi, 2015, Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years, Eur Urol, 67, 299, 10.1016/j.eururo.2014.02.011

Claeys, 2015, Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome, Biomed Res Int, 2015, 198543, 10.1155/2015/198543

Rischke, 2015, Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only, Strahlenther Onkol, 191, 310, 10.1007/s00066-014-0763-5

Tilki, 2015, Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy, J Urol, 193, 484, 10.1016/j.juro.2014.08.096

Linxweiler, 2018, Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: perioperative and early oncological outcomes, Surg Oncol, 27, 138, 10.1016/j.suronc.2018.02.010

Maurer, 2019, (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer, Eur Urol, 75, 659, 10.1016/j.eururo.2018.03.013

Herlemann, 2017, Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients, Oncotarget, 8, 84180, 10.18632/oncotarget.21118

Zattoni, 2016, Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post-radical prostatectomy, Eur Urol Focus, 2, 522, 10.1016/j.euf.2016.01.008

Siriwardana, 2017, Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited, BJU Int, 120, 673, 10.1111/bju.13919

Jilg, 2017, Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT before salvage lymph node dissection for recurrent prostate cancer, Theranostics, 7, 1770, 10.7150/thno.18421

Porres, 2017, The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer, Prostate Cancer Prostatic Dis, 20, 85, 10.1038/pcan.2016.54

Montorsi, 2017, Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer, Eur Urol, 72, 432, 10.1016/j.eururo.2016.08.051

Passoni, 2014, Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series, Urol Oncol, 32, 10.1016/j.urolonc.2013.03.006

Osmonov, 2016, Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection, BMC Urol, 16, 56, 10.1186/s12894-016-0173-3

Abreu, 2017, Robotic salvage retroperitoneal and pelvic lymph node dissection for ‘node-only’ recurrent prostate cancer: technique and initial series, BJU Int, 120, 401, 10.1111/bju.13741

Rauscher, 2016, Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy, J Nucl Med, 57, 1713, 10.2967/jnumed.116.173492

Pfister, 2016, Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with(18)F-fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 43, 1410, 10.1007/s00259-016-3366-9

Rauscher, 2017, Value of (111)In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up, BJU Int, 120, 40, 10.1111/bju.13713

Mandel P, Tilki D, Chun FK, et al. Accuracy of (68)Ga-prostate-specific membrane antigen positron emission tomography for the detection of lymph node metastases before salvage lymphadenectomy. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2018.07.025.

Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012. http://www.ihe.ca/documents/Case%20series%20studies%20using%20a%20modified%20Delphi%20technique.pdf.

Evangelista, 2016, Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis, Nucl Med Commun, 37, 1223, 10.1097/MNM.0000000000000582

Hanske J, Müller G, van Ophoven A, et al. De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer. Neurourol Urodyn. In press. https://doi.org/10.1002/nau.23545.

Ost, 2016, Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis, Eur Urol, 69, 9, 10.1016/j.eururo.2015.07.004